Showing results (121-130 of 481) with videos related to
Sort By:
Pageof 49
Journal of the American College of Cardiology|February 5, 2025
Long-Term Lipid Lowering With Evolocumab in Older IndividualsSamer Al Said, Michelle L O'Donoghue, Xinhui Ran, et al.European Heart Journal|March 15, 2008
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18David A Morrow, Marc S Sabatine, Marie-Luise Brennan, et al.Journal of the American College of Cardiology|October 26, 2019
Long-Term Efficacy and Safety of Evolocumab in Patients With HypercholesterolemiaMichael J Koren, Marc S Sabatine, Robert P Giugliano, et al.Clinical Chemistry|November 19, 2011
Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trialPayal Kohli, Marc P Bonaca, Rahul Kakkar, et al.American Heart Journal|November 8, 2002
Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administrationHoward A Cooper, James A de Lemos, David A Morrow, et al.The American Journal of Cardiology|September 5, 2006
Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28)C Michael Gibson, Hung Q Ly, Sabina A Murphy, et al.Plos One|June 17, 2014
Increases in myocardial workload induced by rapid atrial pacing trigger alterations in global metabolismAslan T Turer, Gregory D Lewis, John F O'Sullivan, et al.Plos One|April 11, 2022
No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumabLaura E Korthauer, Robert P Giugliano, Jianping Guo, et al.Circulation|February 13, 2003
Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromesJames A de Lemos, David A Morrow, Marc S Sabatine, et al.Journal of Cardiovascular Pharmacology and Therapeutics|May 18, 2018
Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment ImplicationsScott M Wasserman, Marc S Sabatine, Michael J Koren, et al.Pageof 49